These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 19907153

  • 21. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 22. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Pagano L, Prossomariti L.
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M, Ali W, Anwar M, Waqar A, Khan MN, Ijaz A, Hussain T, Hussain S.
    J Ayub Med Coll Abbottabad; 2005 Jul; 17(4):12-5. PubMed ID: 16599026
    [Abstract] [Full Text] [Related]

  • 24. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Jul; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

  • 25. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 26. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
    Bentley A, Gillard S, Spino M, Connelly J, Tricta F.
    Pharmacoeconomics; 2013 Sep; 31(9):807-22. PubMed ID: 23868464
    [Abstract] [Full Text] [Related]

  • 27. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N.
    Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
    [Abstract] [Full Text] [Related]

  • 28. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Dec; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 29. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Dec; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 30. Deferiprone: new preparation. Poorly assessed.
    Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
    [Abstract] [Full Text] [Related]

  • 31. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
    Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera MA, Giua R, Sebastio AM, Suma V, De Marco S, Semeraro F, Moscogiuri R.
    Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
    [Abstract] [Full Text] [Related]

  • 32. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Jun; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 33. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 34. Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.
    Sooriyaarachchi M, Gailer J.
    Dalton Trans; 2010 Aug 28; 39(32):7466-73. PubMed ID: 20623073
    [Abstract] [Full Text] [Related]

  • 35. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr 28; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 36. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 Apr 28; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 37. Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.
    Dadheech S, Rao AV, Shaheen U, Hussien MD, Jain S, Jyothy A, Munshi A.
    Gene; 2013 Dec 01; 531(2):301-5. PubMed ID: 24036429
    [Abstract] [Full Text] [Related]

  • 38. Deferiprone.
    Piga A, Roggero S, Salussolia I, Massano D, Serra M, Longo F.
    Ann N Y Acad Sci; 2010 Aug 01; 1202():75-8. PubMed ID: 20712776
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2010 Jun 01; 34(3):204-9. PubMed ID: 20524810
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.